Doxorubicin hydrochloride is a specialty chemical widely used as an antineoplastic agent in the treatment of various types of cancer, including breast cancer, bladder cancer, Kaposi's sarcoma, lymphoma, and acute lymphocytic leukemia. It functions primarily by intercalating into DNA and inhibiting topoisomerase II, which disrupts DNA replication and transcription, thereby inhibiting nucleic acid synthesis and preventing cancer cell proliferation. Administered intravenously, often in combination chemotherapy regimens to improve efficacy and minimize resistance, it is also employed in neoadjuvant therapy to shrink tumors before surgery, adjuvant therapy post-primary treatments like surgery or radiation, and palliative care for advanced disease. Due to its potent cardiotoxicity, which can cause severe heart damage with cumulative doses, its use requires careful monitoring. Liposomal formulations have been developed to enhance tumor targeting, reduce systemic exposure, and mitigate cardiac risks.